Lipella Pharmaceuticals Inc.

NasdaqCM LIPO

Lipella Pharmaceuticals Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Lipella Pharmaceuticals Inc. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Lipella Pharmaceuticals Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -2.67 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: LIPO

Lipella Pharmaceuticals Inc.

CEO	Dr. Jonathan Kaufman M.B.A., Ph.D.
IPO Date	Dec. 19, 2022
Location	United States
Headquarters	7800 Susquehanna St.
Employees	5
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Key trends

Past 5 years